{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T03:49:44Z","timestamp":1782100184096,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"NATCO"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40801-026-00554-w","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T09:54:54Z","timestamp":1776678894000},"page":"253-264","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Relevance of Lenvatinib in Advanced Hepatocellular Carcinoma: Insights from a Prospective Observational Cohort in South India"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2219-889X","authenticated-orcid":false,"given":"Joe","family":"Jose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4965-8012","authenticated-orcid":false,"given":"Shibu V.","family":"Ignatious","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0567-5253","authenticated-orcid":false,"given":"Thattungal Manoharan","family":"Anoop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"issue":"3","key":"554_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"554_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2024.101447","volume":"14","author":"S Giri","year":"2024","unstructured":"Giri S, Singh A. Epidemiology of hepatocellular carcinoma in India: an updated review for 2024. J Clin Exp Hepatol. 2024;14(6):101447. https:\/\/doi.org\/10.1016\/j.jceh.2024.101447.","journal-title":"J Clin Exp Hepatol"},{"issue":"4","key":"554_CR3","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u201390. https:\/\/doi.org\/10.1056\/NEJMoa0708857.","journal-title":"N Engl J Med"},{"issue":"10126","key":"554_CR4","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al. Lenvatinib versus Sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(18)30207-1.","journal-title":"Lancet"},{"issue":"20","key":"554_CR5","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905. https:\/\/doi.org\/10.1056\/NEJMoa1915745.","journal-title":"N Engl J Med"},{"key":"554_CR6","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022. https:\/\/doi.org\/10.1056\/EVIDoa2100070.","journal-title":"NEJM Evid."},{"issue":"10492","key":"554_CR7","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","volume":"405","author":"T Yau","year":"2025","unstructured":"Yau T, Galle PR, Decaens T, et al. Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet. 2025;405(10492):1851\u201364. https:\/\/doi.org\/10.1016\/S0140-6736(25)00403-9.","journal-title":"Lancet"},{"issue":"3","key":"554_CR8","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1053\/j.gastro.2021.06.008","volume":"161","author":"PK Haber","year":"2021","unstructured":"Haber PK, Puigveh\u00ed M, Castet F, et al. Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002\u20132020). Gastroenterology. 2021;161(3):879\u201398. https:\/\/doi.org\/10.1053\/j.gastro.2021.06.008.","journal-title":"Gastroenterology"},{"issue":"8","key":"554_CR9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","volume":"147","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147(8):573\u20137. https:\/\/doi.org\/10.7326\/0003-4819-147-8-200710160-00010.","journal-title":"Ann Intern Med"},{"key":"554_CR10","unstructured":"Elm E von, Altman DG, Egger M, Pocock SJ, Vandenbroucke JP. The STROBE reporting checklist. The EQUATOR network reporting guideline platform. The UK EQUATOR Centre. 2025. https:\/\/www.equator-network.org\/wp-content\/uploads\/2015\/10\/STROBE_checklist_v4_cohort.pdf."},{"issue":"1","key":"554_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000512239","volume":"10","author":"MJ Goh","year":"2021","unstructured":"Goh MJ, Oh JH, Park Y, et al. Efficacy and safety of Lenvatinib therapy for unresectable hepatocellular carcinoma in a real-world practice in Korea. Liver Cancer. 2021;10(1):52\u201362. https:\/\/doi.org\/10.1159\/000512239.","journal-title":"Liver Cancer"},{"issue":"5","key":"554_CR12","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1159\/000508901","volume":"9","author":"J Cheon","year":"2020","unstructured":"Cheon J, Chon HJ, Bang Y, et al. Real-world efficacy and safety of Lenvatinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis. Liver Cancer. 2020;9(5):613\u201324. https:\/\/doi.org\/10.1159\/000508901.","journal-title":"Liver Cancer"},{"issue":"3","key":"554_CR13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1159\/000521746","volume":"11","author":"S Welland","year":"2022","unstructured":"Welland S, Leyh C, Finkelmeier F, et al. Real-world data for lenvatinib in hepatocellular carcinoma (ELEVATOR): a retrospective multicenter study. Liver Cancer. 2022;11(3):219\u201332. https:\/\/doi.org\/10.1159\/000521746.","journal-title":"Liver Cancer"},{"issue":"6","key":"554_CR14","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1159\/000525145","volume":"11","author":"A Casadei-Gardini","year":"2022","unstructured":"Casadei-Gardini A, Rimini M, Kudo M, et al. Real life study of lenvatinib therapy for hepatocellular carcinoma: RELEVANT study. Liver Cancer. 2022;11(6):527\u201339. https:\/\/doi.org\/10.1159\/000525145.","journal-title":"Liver Cancer"},{"issue":"5","key":"554_CR15","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1007\/s12072-022-10398-5","volume":"16","author":"K Patwala","year":"2022","unstructured":"Patwala K, Prince DS, Celermajer Y, et al. Lenvatinib for the treatment of hepatocellular carcinoma: a real-world multicenter Australian cohort study. Hepatol Int. 2022;16(5):1170\u20138. https:\/\/doi.org\/10.1007\/s12072-022-10398-5.","journal-title":"Hepatol Int"},{"issue":"21","key":"554_CR16","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.2217\/fon-2021-0242","volume":"17","author":"AG Singal","year":"2021","unstructured":"Singal AG, Nagar SP, Hitchens A, Davis KL, Iyer S. Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA. Future Oncol. 2021;17(21):2759\u201368. https:\/\/doi.org\/10.2217\/fon-2021-0242.","journal-title":"Future Oncol"},{"key":"554_CR17","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2147\/CEG.S256691","volume":"13","author":"K Ogushi","year":"2020","unstructured":"Ogushi K, Chuma M, Uojima H, et al. Safety and efficacy of lenvatinib treatment in Child-Pugh A and B patients with unresectable hepatocellular carcinoma in clinical practice: a multicenter analysis. Clin Exp Gastroenterol. 2020;13:385\u201396. https:\/\/doi.org\/10.2147\/CEG.S256691.","journal-title":"Clin Exp Gastroenterol"},{"issue":"3","key":"554_CR18","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s12072-023-10498-w","volume":"17","author":"T Prabhakar","year":"2023","unstructured":"Prabhakar T, Kaushal K, Prasad M, et al. Etiologic fractions in patients of hepatocellular carcinoma in India with and without a background of cirrhosis: a multi-centric study. Hepatol Int. 2023;17(3):745\u201352. https:\/\/doi.org\/10.1007\/s12072-023-10498-w.","journal-title":"Hepatol Int"},{"issue":"2","key":"554_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020381","volume":"15","author":"R Sacco","year":"2023","unstructured":"Sacco R, Ramai D, Tortora R, et al. Role of etiology in hepatocellular carcinoma patients treated with lenvatinib: a counterfactual event-based mediation analysis. Cancers (Basel). 2023;15(2):381. https:\/\/doi.org\/10.3390\/cancers15020381.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"554_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-96089-x","volume":"11","author":"A Hiraoka","year":"2021","unstructured":"Hiraoka A, Kumada T, Tada T, et al. Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study. Sci Rep. 2021;11(1):16663. https:\/\/doi.org\/10.1038\/s41598-021-96089-x.","journal-title":"Sci Rep"},{"issue":"6","key":"554_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100330","volume":"6","author":"M Rimini","year":"2021","unstructured":"Rimini M, Kudo M, Tada T, et al. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib. ESMO Open. 2021;6(6):100330. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100330.","journal-title":"ESMO Open"},{"issue":"11","key":"554_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17111808","volume":"17","author":"R Sacco","year":"2025","unstructured":"Sacco R, Giannini EG, Tortora R, et al. Lenvatinib is highly effective in patients with hepatocellular carcinoma related to both metabolic dysfunction-associated steatohepatitis and alcoholic etiology: a propensity score analysis. Cancers (Basel). 2025;17(11):1808. https:\/\/doi.org\/10.3390\/cancers17111808.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"554_CR23","doi-asserted-by":"publisher","first-page":"147","DOI":"10.14218\/JCTH.2021.00179","volume":"10","author":"ZJ Deng","year":"2022","unstructured":"Deng ZJ, Li L, Teng YX, et al. Treatments of hepatocellular carcinoma with portal vein tumor thrombus: current status and controversy. J Clin Transl Hepatol. 2022;10(1):147\u201358. https:\/\/doi.org\/10.14218\/JCTH.2021.00179.","journal-title":"J Clin Transl Hepatol"},{"issue":"3","key":"554_CR24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.livres.2024.09.002","volume":"8","author":"W Abdelhamed","year":"2024","unstructured":"Abdelhamed W, Shousha H, El-Kassas M. Portal vein tumor thrombosis in hepatocellular carcinoma patients: is it the end? Liver Res. 2024;8(3):141\u201351. https:\/\/doi.org\/10.1016\/j.livres.2024.09.002.","journal-title":"Liver Res"},{"issue":"8","key":"554_CR25","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.hpb.2017.04.016","volume":"19","author":"JP Silva","year":"2017","unstructured":"Silva JP, Berger NG, Tsai S, et al. Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis. HPB (Oxford). 2017;19(8):659\u201366. https:\/\/doi.org\/10.1016\/j.hpb.2017.04.016.","journal-title":"HPB (Oxford)"},{"issue":"23","key":"554_CR26","first-page":"7543","volume":"25","author":"HY Tsai","year":"2021","unstructured":"Tsai HY, Chang HP, Chen CJ, Hsu WL, Huang LY, Lee PC. Effects of direct-acting antiviral therapy for patients with advanced hepatocellular carcinoma and concomitant hepatitis C: a population-based cohort study. Eur Rev Med Pharmacol Sci. 2021;25(23):7543\u201352.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"12","key":"554_CR27","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1002\/kjm2.12757","volume":"39","author":"Y Hsiao","year":"2023","unstructured":"Hsiao Y, Sou F, Wang J, et al. Well\u2010controlled viremia reduces the progression of hepatocellular carcinoma in chronic viral hepatitis patients treated with lenvatinib. Kaohsiung J Med Sci. 2023;39(12):1233\u201342. https:\/\/doi.org\/10.1002\/kjm2.12757.","journal-title":"Kaohsiung J Med Sci"},{"issue":"10408","key":"554_CR28","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chan SL, Gu S, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402(10408):1133\u201346. https:\/\/doi.org\/10.1016\/S0140-6736(23)00961-3.","journal-title":"Lancet"},{"issue":"6","key":"554_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100591","volume":"7","author":"M Rimini","year":"2022","unstructured":"Rimini M, Rimassa L, Ueshima K, et al. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis. ESMO Open. 2022;7(6):100591. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100591.","journal-title":"ESMO Open"},{"issue":"7854","key":"554_CR30","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","volume":"592","author":"D Pfister","year":"2021","unstructured":"Pfister D, N\u00fa\u00f1ez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592(7854):450\u20136. https:\/\/doi.org\/10.1038\/s41586-021-03362-0.","journal-title":"Nature"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00554-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-026-00554-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00554-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T03:19:31Z","timestamp":1782098371000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-026-00554-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["554"],"URL":"https:\/\/doi.org\/10.1007\/s40801-026-00554-w","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"9 April 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Joe Jose, Shibu V. Ignatious, and Anoop T. Manohar have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Ethics Committee of Regional Cancer Centre, Thiruvananthapuram, India (IEC Number 07\/2023\/04).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent to participate in the study was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated during and\/or analyzed during the current study are available on reasonable request to the corresponding author.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization: JJ, SI, AM; data curation: JJ; formal analysis: JJ, SI; funding acquisition: not applicable; investigation: JJ, SI, AM; methodology: JJ, SI, AM; project administration: JJ, SI, AM; resources: AM; software: AM; supervision; AM; validation: JJ, SI, AM; visualization: JJ, SI, AM; roles\/writing (original draft): JJ, SI; writing (review and editing): JJ, SI, AM. All authors read and approved the final version.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"The authors declare no use of AI for the write-up of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI and AI-assisted technologies in the writing process"}}]}}